Cooper Financial Group purchased a new position in shares of Astrazeneca Plc (NYSE:AZN - Free Report) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 6,342 shares of the company's stock, valued at approximately $1,203,000.
A number of other institutional investors have also modified their holdings of the company. Mascoma Wealth Management LLC purchased a new stake in Astrazeneca in the 1st quarter valued at about $26,000. MV Capital Management Inc. acquired a new stake in shares of Astrazeneca in the fourth quarter worth approximately $26,000. Roxbury Financial LLC purchased a new stake in Astrazeneca in the second quarter valued at approximately $29,000. Reflection Asset Management purchased a new stake in Astrazeneca in the fourth quarter valued at approximately $31,000. Finally, Resources Management Corp CT ADV acquired a new position in Astrazeneca during the first quarter worth approximately $35,000. Institutional investors and hedge funds own 20.35% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on AZN. Sanford C. Bernstein reaffirmed a "buy" rating on shares of Astrazeneca in a research note on Monday, May 4th. Jefferies Financial Group reaffirmed a "buy" rating on shares of Astrazeneca in a research report on Friday, June 26th. DZ Bank upgraded Astrazeneca from a "neutral" rating to a "buy" rating in a report on Wednesday, April 29th. Wall Street Zen downgraded Astrazeneca from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Finally, Weiss Ratings downgraded Astrazeneca from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, July 28th. Twelve research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $211.00.
Read Our Latest Stock Report on Astrazeneca
Astrazeneca Stock Up 0.1%
Shares of Astrazeneca stock opened at $161.28 on Friday. Astrazeneca Plc has a twelve month low of $145.79 and a twelve month high of $212.71. The stock has a market cap of $250.12 billion, a price-to-earnings ratio of 24.11, a price-to-earnings-growth ratio of 1.39 and a beta of 0.26. The company has a current ratio of 0.89, a quick ratio of 0.67 and a debt-to-equity ratio of 0.47. The company has a fifty day moving average price of $176.34 and a 200 day moving average price of $187.11.
Astrazeneca (NYSE:AZN - Get Free Report) last issued its quarterly earnings data on Monday, July 27th. The company reported $2.63 EPS for the quarter, topping analysts' consensus estimates of $2.50 by $0.13. The company had revenue of $15.38 billion for the quarter, compared to analysts' expectations of $15.44 billion. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The firm's quarterly revenue was up 6.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.17 earnings per share. Equities research analysts forecast that Astrazeneca Plc will post 10.22 earnings per share for the current fiscal year.
About Astrazeneca
(
Free Report)
AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.
The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Astrazeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrazeneca wasn't on the list.
While Astrazeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
